OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Hematology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Hemophagocytic lymphohistiocytosis in Egyptian children: diagnosis, treatment challenges, and outcome	67
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care	56
What is the future of digital tools to help manage pain in sickle cell disease patients?	43
Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP	42
Are we closer to a standard of care for Richter’s syndrome? Novel treatments on the horizon	37
Treatment patterns and blood count control in 10,112 patients with polycythemia vera	33
Do we need more guidance on thrombophilia testing? Challenges and special considerations	27
The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease	25
Treating sickle cell disease in resource-limited sub-Saharan Africa: recent strategies and recommendations in addressing the gaps for the provision of evidence-based management	24
Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic l	24
Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management	24
Past, present, and future of orthopedic surgery in hemophilia: looking to a world without bleeding and arthropathy in the near future	23
Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective	20
Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B	19
Correlation between hematocrit and the risk of common human cancers: results of a 1999–2020 observational survey and Mendelian randomization analysis	19
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations	18
Improving endpoints for sickle cell disease clinical trials: retaining consistency and clinical benefit	18
BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia	18
The future of siRNA-mediated approaches to treat von Willebrand disease	17
Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera	16
Screening and interventional strategies for the late effects and toxicities of hematological malignancy treatments in pediatric survivors	16
Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women	16
Current trends and future artificial intelligence applications in transfusion medicine: a bibliometric analysis	16
ADAMTS13 activity and clinical outcomes: a targeted literature review in congenital thrombotic thrombocytopenic purpura and other related thrombotic conditions	15
Late effects of hemopoietic stem cell transplant for sickle cell disease: monitoring and management	15

Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A	15
Rilzabrutinib for persistent or chronic immune thrombocytopenia (ITP): a Bruton tyrosine kinase inhibitor that can target multiple pathophysiological pathways	15
Impact of atrial fibrillation in onco-hematological patients in Europe: a targeted literature review	14
Bone marrow aspirate or biopsy for multiple myeloma: when percentages matter!	14
Patient-centered care in von Willebrand disease: are we there yet?	14
Efficacy and safety of phosphatidylinositol 3-kinase inhibitors in patients with chronic lymphocytic leukemia: a meta-analysis and systematic review	14
Can minimal residual disease be used to tailor therapy duration for chronic lymphocytic leukemia patients?	13
Managing blood supplies during natural disasters, humanitarian emergencies, and pandemics: lessons learned from COVID-19	13
Transfusion efficacy and adverse events of a restrictive transfusion strategy in patients with acute upper gastrointestinal bleeding	13
Apparent plateaus during iron chelation in transfusion-dependent β-thalassemia: interpretation and clinical implications	13
New directions to develop therapies for people with hemophilia	13
Review, conceptual model, and gap analysis of transfusion burden in hematological diseases	13
The National Hemophilia Foundation’s State of the Science Research Summit: the foundation of a national research blueprint for inherited bleeding disorders	12
Development and internal validation of a prediction model for patients with hematologic diseases of fall risk: a cohort study	12
Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies	12
BCL-2 inhibition in acute myeloid leukemia: resistance and combinations	12
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding	12
Expression and prognostic value of cytotoxic T-lymphocyte-associated 4 protein in classic Hodgkin lymphoma	12
DGPCNet: anemia detection from multimodal palm, fingernails, and eye conjunctiva images using deep global pyramid convolutional network	11
Is next-generation sequencing the future of measurable residual disease assays for Philadelphia chromosome-positive acute lymphoblastic leukemia?	11
Hematology in the post-COVID era: spotlight on vaccine-induced immune thrombotic thrombocytopenia and a conceptual framework (the 4P’s) for anti-PF4 diseases	11
Is the occurrence of deep vein thrombosis related to the fracture site? A two-sample Mendelian randomization study	11
Plain language summary: a phase 2/3 study of plasminogen, human-tvmh for the treatment of children and adults with type 1 plasminogen deficiency	11
Optimizing long-term joint health in the treatment of hemophilia	11
Bad players in AL amyloidosis in the current era of treatment	11
Endogenous erythroid colony formation in the era of contemporary polycythemia vera diagnosis	11
Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours	11
Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes	11
Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia	11
Social challenges and support needs of patients with hemophilia in Pakistan: a qualitative exploratory study	10
Rivaroxaban plus aspirin after lower–extremity revascularization	10
Real-world treatment patterns and outcomes in people with von Willebrand disease treated prophylactically with recombinant von Willebrand factor in the United States	10
Oral decitabine in acute myeloid leukemia: assessing efficacy, safety, and future implications for older patients	10
The association between hemoglobin level, anemia, and hypertension among adolescents in Sudan: a multicenter cross-sectional study	10
Embedding cardiovascular risk assessment into routine BTK inhibitor management in chronic lymphocytic leukemia	9
Long-term follow-up of patients with hairy cell leukemia in the south of Iran	9
Sickle cell disease in gulf cooperation council countries: a systematic review	9
The impact of oral health promotion on the quality of life of children with bleeding disorders: fighting misconceptions	9
What is the importance of monitoring iron levels in different organs over time with magnetic resonance imaging in transfusion-dependent thalassemia patients?	9
A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS	9
A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors	9
An update on novel therapies for treating patients with arterial thrombosis	9
Lived experience experts: a name created by us for us	9
Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria	9
Indicators of an increased risk of therapy-related myeloid neoplasms in lymphoma patients: how can we best evaluate severe impairment of bone marrow function?	9
Novel mechanisms of action of emerging therapies of hereditary thrombotic thrombocytopenic purpura	9
Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia	8
Trends of chronic lymphocytic leukemia incidence and mortality in the United States: a population-based study over the last four decades	8
Advances in our understanding of genetic markers and targeted therapies for pediatric LCH	8
Curative effect of motherwort combined with ethinylestradiol-cyproterone acetate on dysfunctional uterine bleeding	8

Bridging the gap: how do we enroll more racial-ethnic minority patients in hematological drug trials?	8
Sutimlimab for cold agglutinin disease: an updated perspective from approval to real-world clinical treatment	8
Role of volumetric analyses on [¹⁸F]FDG PET/CT in pediatric Hodgkin lymphoma	8
Myelofibrosis treatment sequencing: mutation-informed risk and optimal JAK inhibitor discontinuation	8
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for mucocutaneous bleeding disorders	8
Circ_0035381 contributes to the progression of acute myeloid leukemia via regulating miR-186-5p/CDCA3 pathway	8
Stem cell boost for immune effector cell associated hematotoxicity in multiple myeloma: minimizing long-term complications and expanding post CAR T-cell therapy relapse options	8
Novel therapeutics for immune thrombocytopenia: an evolving treatment landscape	8
Mesenchymal stromal cells for the prophylaxis of graft-versus-host disease after hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials	8
Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directions	8
Genetic variant of endothelial protein C receptor genes and its serum level in B thalassemic children	8
Pain in sickle cell disease: a prospective multicentre community-based cohort study in underserved Indian communities	8
Problems faced by people with hemophilia aged 18–35 years in social life: a qualitative study	8
Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis	7
An observational study of disease management in adult patients with polycythemia vera: results from a large U.S. claims database	7
Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them	7
An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency	7
Identifying prognostic gene panels in acute myeloid leukemia	7
Evaluating quality-of-life outcomes during decitabine therapy in older adults with acute myeloid leukemia: overview of reported studies and assessment instruments	7
Exploring health disparities in diagnosing multiple myeloma	7
Development of CD30 CAR-T cells in refractory or relapsed Hodgkin’s lymphoma	7
Targeting von Willebrand disease: the current status and future directions of management therapies	7
Challenges in the diagnosis of thrombotic thrombocytopenic purpura	7
May obesity increase the risk of lymphoma? Insights from genetic evidence	7
Reassuring clinicians and patients using SGLT-2 inhibitors: is there a need to worry about blood complications?	7
Advances in stem cell transplantation for Fanconi anemia	7
Kompetitive allele specific PCR (KASP) based genotyping of sickle gene in the selected sub-ethnic tribal population of Gujarat and Madhya Pradesh	7
Changes in circular RNA expression in acute chest syndrome and vaso-occlusive crisis in sickle cell disease: analysis of a public RNA-seq cohort	7
Revisiting the role of measurable residual disease in FLT3 mutated acute myelogenous leukemia	7
Real-world analysis and cost-effectiveness of iron chelation therapy adherence in transfusion-dependent thalassemia	7
Treatment of systemic mastocytosis with associated hematologic neoplasm: midostaurin and beyond	7
An interview with Dr Joshua Richter on his experience as an investigator for linvoseltamab-gcpt - by Reegan Burnell-Clarke (Commissioning Editor)	7
Exploring the genetic relationship between deep vein thrombosis and plasma protein: a new research idea	6
Polycythemia vera and metabolic syndrome: is the relationship between the two diseases more than we think?	6
Revolutionizing hypertension treatment: aprocitentan’s dual action against resistant hypertension	6
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia	6
Navigating the gap between guidelines and practical challenges in selecting first-line therapy for chronic lymphocytic leukemia	6
How clinicians and persons with hemophilia may approach shared decision-making	6
Specifically targeting the ABL myristoyl pocket: STAMP inhibitors for chronic myeloid leukemia	6
Incidence, prevention and management of severe infections in patients undergoing therapy for chronic lymphocytic leukemia	6
Gene therapy in the treatment of hemophilia A: a systematic review and meta-analysis	6
NSAIDS/COXIBS for the treatment of musculoskeletal pain secondary to hemophilic arthropathy	6
Avoiding serious treatment-emergent adverse events in Waldenström macroglobulinemia patients	6
Understanding the interplay between chronic lymphocytic leukemia and type 2 diabetes	6
Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison	6